Emtricitabine + tenofovir

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.5. Fixed-dose combinations of antiretrovirals

Codes ATC: J05AR03

Indication	Contact with or exposure to human immunodeficiency virus Code ICD11: QC90.6
INN	Emtricitabine + tenofovir
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	**Oral > Solid:** 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2021 (TRS 1035)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	lamivudine + tenofovir (Codes ATC: J05AR12)
Renseignements sur le brevet	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Lire la suite sur les brevets.
Wikipédia	Emtricitabine + tenofovir
DrugBank	Emtricitabine, Tenofovir (Tenofovir disoproxil)

Résumé des preuves et recommandation du comité d'experts

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified a as therapeutic alternative for the emtricitabine component under the square box listing for emtricitabine + tenofovir on the EML.